TW202229351A - 新穎之抗cd47抗體及其用途 - Google Patents

新穎之抗cd47抗體及其用途 Download PDF

Info

Publication number
TW202229351A
TW202229351A TW110138242A TW110138242A TW202229351A TW 202229351 A TW202229351 A TW 202229351A TW 110138242 A TW110138242 A TW 110138242A TW 110138242 A TW110138242 A TW 110138242A TW 202229351 A TW202229351 A TW 202229351A
Authority
TW
Taiwan
Prior art keywords
antibody
cells
cdata
cancer
seq
Prior art date
Application number
TW110138242A
Other languages
English (en)
Chinese (zh)
Inventor
王正毅
曹巍
郭炳詩
徐聰
Original Assignee
中國大陸商天境生物科技（上海）有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中國大陸商天境生物科技（上海）有限公司 filed Critical 中國大陸商天境生物科技（上海）有限公司
Publication of TW202229351A publication Critical patent/TW202229351A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW110138242A 2020-10-14 2021-10-14 新穎之抗cd47抗體及其用途 TW202229351A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
WOPCT/CN2020/120869 2020-10-14
CN2020120869 2020-10-14
WOPCT/CN2020/122188 2020-10-20
CN2020122188 2020-10-20

Publications (1)

Publication Number Publication Date
TW202229351A true TW202229351A (zh) 2022-08-01

Family

ID=81207683

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110138242A TW202229351A (zh) 2020-10-14 2021-10-14 新穎之抗cd47抗體及其用途

Country Status (12)

Country Link
US (1) US20230399400A1 (https=)
EP (1) EP4229088A1 (https=)
JP (1) JP2023546277A (https=)
KR (1) KR20230114745A (https=)
CN (1) CN116348601A (https=)
AU (1) AU2021360633A1 (https=)
CA (1) CA3198895A1 (https=)
CO (1) CO2023005611A2 (https=)
IL (1) IL302112A (https=)
MX (1) MX2023004223A (https=)
TW (1) TW202229351A (https=)
WO (1) WO2022078465A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017332960B2 (en) 2016-10-20 2019-09-12 I-Mab Biopharma Us Limited Novel CD47 monoclonal antibodies and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017332960B2 (en) * 2016-10-20 2019-09-12 I-Mab Biopharma Us Limited Novel CD47 monoclonal antibodies and uses thereof
WO2019091473A1 (en) * 2017-11-10 2019-05-16 I-Mab Biopharma Co., Ltd. Fusion proteins containing cd47 antibodies and cytokines
WO2020036977A1 (en) * 2018-08-13 2020-02-20 Arch Oncology, Inc. Therapeutic cd47 antibodies
AU2019370754A1 (en) * 2018-10-31 2021-02-04 I-Mab Biopharma Us Limited Novel CD47 antibodies and methods of using same
CA3097443A1 (en) * 2018-11-12 2020-05-22 I-Mab Biopharma Us Limited Fusion proteins containing cd47 antibodies and cytokines

Also Published As

Publication number Publication date
WO2022078465A1 (en) 2022-04-21
KR20230114745A (ko) 2023-08-01
EP4229088A1 (en) 2023-08-23
US20230399400A1 (en) 2023-12-14
MX2023004223A (es) 2023-08-03
AU2021360633A9 (en) 2025-01-09
CA3198895A1 (en) 2022-04-21
CO2023005611A2 (es) 2023-05-29
JP2023546277A (ja) 2023-11-01
IL302112A (en) 2023-06-01
CN116348601A (zh) 2023-06-27
AU2021360633A1 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
US11485782B2 (en) Anti-claudin 18.2 antibodies
US12458818B2 (en) Anti-trophoblast cell surface antigen 2 (TROP2) antibodies and antibody drug conjugates comprising same
US11708410B2 (en) Antibodies and variants thereof against TIGIT
AU2018366650B2 (en) Single-domain antibodies and variants thereof against PD-L1
US11713353B2 (en) Single-domain antibodies and variants thereof against PD-1
EP3838289A1 (en) Anti-tigit antibody and uses thereof
EP3774917B1 (en) Single-domain antibodies against lag-3 and uses thereof
US20180171017A1 (en) Combined use of immune activators
US20220289848A1 (en) Anti-cd47/anti-pd-l1 multiple antigen binding proteins and methods of use thereof
JP2019031552A (ja) Ｐｄ−１系結合アンタゴニストおよび抗ｇｐｃ３抗体を使用して癌を治療する方法
US20240287204A1 (en) Anti-mertk antibodies and methods of use thereof
TW202124442A (zh) 人源化抗ｃｌｄｎ１８．２抗體、編碼其的核酸分子、其產生方法、包含其的組合物、試劑盒及其用途
US20210122817A1 (en) Anti-ms4a6a antibodies and methods of use thereof
JP2021512613A (ja) 二重特異性抗原結合分子及びその使用方法
TW202229351A (zh) 新穎之抗cd47抗體及其用途
EP4624492A1 (en) Anti-ccr8 antibody and use thereof
JP2023513059A (ja) 抗ミューラー管ホルモン受容体２抗体及び使用方法
WO2025119313A1 (en) Novel anti-cd47 antibodies and uses thereof
HK40091237A (zh) 新型抗cd47抗体及其用途
EP4524158A1 (en) Antibody that specifically recognizes gdf15 and use thereof
TW202434286A (zh) 治療兒童期發病的特發性腎病症候群之組成物及方法
HK40034257B (en) Anti-claudin 18.2 antibodies
HK40034257A (en) Anti-claudin 18.2 antibodies